PNC Financial Services Group’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-7,000
Closed -$22K 4748
2022
Q2
$22K Hold
7,000
﹤0.01% 3465
2022
Q1
$30K Hold
7,000
﹤0.01% 3387
2021
Q4
$33K Hold
7,000
﹤0.01% 3337
2021
Q3
$28K Hold
7,000
﹤0.01% 3378
2021
Q2
$30K Hold
7,000
﹤0.01% 3319
2021
Q1
$30K Hold
7,000
﹤0.01% 3248
2020
Q4
$27K Hold
7,000
﹤0.01% 3217
2020
Q3
$28K Hold
7,000
﹤0.01% 3068
2020
Q2
$30K Hold
7,000
﹤0.01% 3028
2020
Q1
$29K Hold
7,000
﹤0.01% 2942
2019
Q4
$28K Buy
7,000
+2,981
+74% +$17.6K ﹤0.01% 3191
2019
Q3
$35K Hold
4,019
﹤0.01% 3113
2019
Q2
$37K Buy
+4,019
New +$30.3K ﹤0.01% 3099
2017
Q2
Sell
-2,860
Closed -$86K 4369
2017
Q1
$86K Buy
+2,860
New +$73K ﹤0.01% 2591
2016
Q3
Sell
-31
Closed 4728
2016
Q2
$0 Sell
31
-1
-3% -$18 ﹤0.01% 4743
2016
Q1
$1K Buy
32
+1
+3% +$18 ﹤0.01% 4488
2015
Q4
$1K Buy
+31
New +$845 ﹤0.01% 4444

PNC Financial Services Group's LJPC Position: Q3 2022 in Review

PNC Financial Services Group sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 7,000 shares — an estimated $22K sold.

PNC Financial Services Group first reported a position in LJPC in Q4 2015 and held it in 17 quarters. The position peaked at $86K in Q1 2017. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.

  • PNC Financial Services Group reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
  • PNC Financial Services Group sold 7,000 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $22K.
  • PNC Financial Services Group first reported a position in La Jolla Pharmaceutical Company in Q4 2015 and held it in 17 quarters.
  • PNC Financial Services Group's La Jolla Pharmaceutical Company position peaked at $86K in Q1 2017.
  • 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.

Based on PNC Financial Services Group's 13F filing for Q3 2022, filed 10 Nov 2022.